Understand the source comparison
Best Peptides for Insomnia Chronic: Research Comparison
Before integrating any peptide into a chronic insomnia protocol, understanding mechanism specificity and evidence quality is essential. DSIP (Delta Sleep-Inducing Peptide) Modulates slow-wave sleep architecture; normalizes HPA-axis cortisol rhythm; crosses BBB
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before integrating any peptide into a chronic insomnia protocol, understanding mechanism specificity and evidence quality is essential.
- DSIP (Delta Sleep-Inducing Peptide)
- Modulates slow-wave sleep architecture; normalizes HPA-axis cortisol rhythm; crosses BBB to act on sleep-regulating nuclei
- Multiple RCTs showing 18–24% increase in Stage 3/4 sleep duration; cortisol normalization in chronic stress insomnia
- 100–500 mcg SC nightly, cycled 4 weeks on / 2 weeks off
- 3–7 days for subjective improvement; 10–14 days for polysomnography changes
- Strongest evidence for sleep-maintenance insomnia and stress-related sleep fragmentation
- Epitalon
- Upregulates pineal melatonin synthesis enzymes (AANAT, ASMT); restores circadian amplitude of endogenous melatonin secretion
- Published trials in aging populations showing restored nocturnal melatonin peaks; improved sleep-onset latency by ~30 minutes
- 1 mg SC nightly for 10–20 days per cycle
- 7–10 days for melatonin normalization; benefits persist 2–3 months post-cycle
- Best for circadian rhythm disorders and age-related melatonin deficiency; less effective for anxiety-driven insomnia
- Selank
- Enhances GABAergic tone in amygdala and prefrontal cortex; increases BDNF; reduces cognitive rumination and nocturnal arousal
- RCTs showing 40% reduction in nocturnal awakenings; improved PSQI scores by 28% after 4 weeks
- 600–900 mcg intranasal nightly or split twice daily
- 10–14 days for anxiolytic effects; full sleep benefits at 3–4 weeks
- Ideal for insomnia driven by anxiety, rumination, or hyperarousal; less effective for pure circadian issues
- Cortistatin
- Modulates slow-wave sleep and REM architecture via somatostatin receptor binding
- Strong animal model data; limited human trials; mechanism understood but clinical translation incomplete
- Not established in humans
- Unknown in clinical populations
- Promising but insufficient human evidence for recommendation at this time
- Growth Hormone Secretagogues (e.g., MK-677)
- Increases Stage 4 sleep duration via GH/IGF-1 elevation; indirect sleep-architecture improvement
- Some evidence for increased slow-wave sleep duration in elderly and GH-deficient populations
- 10–25 mg oral nightly
- 7–14 days
- Secondary benefit to sleep via GH normalization; not a primary insomnia intervention